Search hospitals

>

Arizona

>

Scottsdale

Mayo Clinic in Arizona

Claim this profile

Scottsdale, Arizona 85259

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Multiple Myeloma

Conducts research for Lung Cancer

Conducts research for Pancreatic Cancer

818 reported clinical trials

81 medical researchers

Photo of Mayo Clinic in Arizona in ScottsdalePhoto of Mayo Clinic in Arizona in ScottsdalePhoto of Mayo Clinic in Arizona in Scottsdale

Summary

Mayo Clinic in Arizona is a medical facility located in Scottsdale, Arizona. This center is recognized for care of Cancer, Breast Cancer, Multiple Myeloma, Lung Cancer, Pancreatic Cancer and other specialties. Mayo Clinic in Arizona is involved with conducting 818 clinical trials across 1,081 conditions. There are 81 research doctors associated with this hospital, such as Mahesh Seetharam, Andrea E. Wahner Hendrickson, M.D., Tanios S. Bekaii-Saab, and Sani Kizilbash, MD, MPH.

Area of expertise

1

Cancer

Global Leader

Mayo Clinic in Arizona has run 115 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRAF positive
2

Breast Cancer

Global Leader

Mayo Clinic in Arizona has run 107 trials for Breast Cancer. Some of their research focus areas include:

ER positive
Stage IV
HER2 negative

Top PIs

Clinical Trials running at Mayo Clinic in Arizona

Breast Cancer

Cancer

Prostate Cancer

Lymphoma

Non-Hodgkin's Lymphoma

Lung Cancer

Chronic Lymphocytic Leukemia

Brain Tumor

Ovarian Cancer

Pancreatic Cancer

Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Image of trial facility.

Proton Therapy

for Breast Cancer

The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wall and regional lymph nodes.

Recruiting

2 awards

Phase 3

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mayo Clinic in Arizona?

Where is Mayo Clinic in Arizona located?

Who should I call to ask about financial aid or insurance network?

What insurance does Mayo Clinic in Arizona accept?

What awards or recognition has Mayo Clinic in Arizona received?